2025-10-09 - Analysis Report
Okay, here's an analysis of Johnson & Johnson (JNJ) based on the provided data.

## JNJ Stock Analysis (October 10, 2025)

**Ticker:** JNJ (Johnson & Johnson)

**Company Overview:**  Johnson & Johnson is a global healthcare company engaged in the research, development, manufacture, and sale of a broad range of products in the healthcare field.

### 1. Performance vs. S&P 500 (VOO)

*   **JNJ Cumulative Return:** 46.07%
*   **VOO Cumulative Return:** 99.62%
*   **Absolute Divergence:** -53.2%
*   **Relative Divergence:** 15.0

**Analysis:** JNJ has significantly underperformed the S&P 500 over the period reflected in the data. The -53.2% absolute divergence indicates a large gap in cumulative returns. The relative divergence of 15.0 suggests that JNJ's underperformance is near the lower end of its historical range compared to the S&P 500.

**Alpha and Beta Analysis:**

| Year       | CAGR   | MDD    | Alpha  | Beta | Cap(B) |
|------------|--------|--------|--------|------|--------|
| 2015-2017  | 26.0%  | 66.8%  | -2.0%  | -0.1 | 336.5  |
| 2016-2018  | 14.0%  | 10.7%  | -1.0%  | 0.1  | 310.8  |
| 2017-2019  | 20.0%  | 71.5%  | -2.0%  | 0.4  | 351.3  |
| 2018-2020  | 19.0%  | 79.2%  | -4.0%  | 0.4  | 379.0  |
| 2019-2021  | 33.0%  | 79.2%  | -14.0% | 0.5  | 412.0  |
| 2020-2022  | 8.0%   | 79.6%  | 9.0%   | 0.4  | 425.4  |
| 2021-2023  | -19.0% | 79.6%  | -20.0% | 0.3  | 377.5  |
| 2022-2024  | -32.0% | 79.6%  | -53.0% | 0.3  | 348.3  |
| 2023-2025  | 17.0%  | 79.6%  | -47.0% | 0.1  | 456.8  |

**Analysis:**

*   **CAGR:** The Compound Annual Growth Rate varies significantly over the periods, with negative growth in recent periods (2021-2025).
*   **MDD:** The Maximum Drawdown is consistently high, indicating significant potential losses from peak to trough.
*   **Alpha:** Alpha is mostly negative, suggesting JNJ has generally underperformed its benchmark on a risk-adjusted basis.  The recent negative alpha values (-53.0%, -47.0%) are particularly concerning.
*   **Beta:** Beta values are generally low (around 0.1 to 0.5), indicating lower volatility than the market.
*   **Cap(B):** The market capitalization has fluctuated but generally increased over time.

### 2. Recent Stock Price Movement

*   **Current Price:** 189.69
*   **Previous Close:** 188.89
*   **Change:** 0.42
*   **5-day Moving Average:** 188.27
*   **20-day Moving Average:** 180.91
*   **60-day Moving Average:** 175.51

**Analysis:** The stock price has increased slightly from the previous close.  The current price is above all three moving averages (5-day, 20-day, and 60-day), which generally indicates an upward trend.  The 5-day moving average being higher than the 20-day and 60-day moving averages further supports this short-term upward momentum.  The change of 0.42 is not large enough to be considered a significant event such as a sudden spike/drop.

### 3. Market Risk Indicators and Expected Return

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended)
*   **RSI:** 87.71 (Overbought)
*   **PPO:** 0.52
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (5 shares - Very Safe - MRI:0.90) Monthly invest 0.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-10-01)
*   **Delta_Previous_Relative_Divergence:** 3.8 (+): Short-term increase
*   **Expected Return:** -115.2% (Long-term, relative to S&P 500)

**Analysis:**

*   **MRI:** A high MRI score suggests a favorable market environment for investment, but this should be considered in conjunction with other factors.
*   **RSI:** An RSI of 87.71 indicates the stock is overbought and may be due for a correction.
*   **PPO:** The PPO (Percentage Price Oscillator) measures the momentum of a stock. 
*   **Hybrid Signal:** The hybrid signal suggests buying JNJ.
*   **Delta_Previous_Relative_Divergence:** The positive change in relative divergence indicates a short-term improvement in JNJ's performance relative to its benchmark.
*   **Expected Return:** A significantly negative expected return (-115.2%) suggests that, based on current conditions, long-term investment in JNJ is projected to underperform the S&P 500 substantially.

### 4. Recent News & Significant Events

*   **Valuation Concerns:** Several articles mention evaluating JNJ's valuation after recent price gains. This suggests the market may be questioning whether the current price is justified.
*   **Potential Upsides:** News about Protagonist Therapeutics' Icotrokinra, analyst upgrades, and the potential to beat earnings estimates again paint a more positive picture.
*   **Tariffs Impact:** The article on tariffs impacting the stock market may be relevant, depending on how pharmaceutical levies affect JNJ's business.
*   **Parkinson's Disease Therapy:** Bayer's positive data on cell therapy for Parkinson's could impact the competitive landscape, although indirectly.

**Analysis:** The news is mixed. While some articles point to potential upsides and positive analyst sentiment, others raise concerns about valuation.

### 4-2. Analyst Opinions

*   **Consensus:** Buy (~2.12)
*   **Target Price:** Average: 186.31, High: 213.00, Low: 155.00

**Analysis:** Analyst consensus is generally positive ("Buy"). However, the average target price (186.31) is below the current price (189.69), suggesting that analysts, on average, believe the stock is slightly overvalued.

### 5. Recent Earnings Analysis

| Date       | EPS  | Revenue       |
|------------|------|---------------|
| 2025-07-24 | 2.30 | 23.74 B$      |
| 2025-04-23 | 4.57 | 21.89 B$      |
| 2024-10-23 | 1.12 | 22.47 B$      |
| 2024-07-25 | 1.95 | 22.45 B$      |
| 2025-07-24 | 1.95 | 22.45 B$      |

**Analysis:** EPS and revenue have fluctuated. The most recent EPS is a re-run of 2024-07-25. The other numbers look more healthy.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter    | Revenue   | Profit Margin |
|------------|-----------|---------------|
| 2025-06-30 | $23.74B   | 67.87%        |
| 2025-03-31 | $21.89B   | 66.40%        |
| 2024-12-31 | $22.52B   | 68.35%        |
| 2024-09-30 | $22.47B   | 69.01%        |
| 2024-06-30 | $22.45B   | 69.40%        |

**Capital and Profitability:**

| Quarter    | Equity    | ROE     |
|------------|-----------|---------|
| 2025-06-30 | $78.47B   | 7.06%   |
| 2025-03-31 | $78.11B   | 14.08%  |
| 2024-12-31 | $71.49B   | 4.80%   |
| 2024-09-30 | $70.16B   | 3.84%   |
| 2024-06-30 | $71.54B   | 6.55%   |

**Analysis:**

*   **Revenue:** Revenue shows some variability but is generally stable.
*   **Profit Margin:** Profit margins are consistently high, indicating strong profitability.
*   **Equity:** Equity has been increasing over the period.
*   **ROE:** ROE (Return on Equity) fluctuates, with the most recent quarter showing an increasing value.

### 7. Overall Summary

Based on the provided data, here's a summary of the key findings:

*   **Underperformance:** JNJ has significantly underperformed the S&P 500, with a large divergence in cumulative returns and mostly negative Alpha values.
*   **Positive Short-Term Momentum:** The recent price movement and moving averages indicate short-term upward momentum.
*   **Overbought Condition:** The high RSI suggests the stock may be overbought and prone to a correction.
*   **Mixed News Sentiment:** Recent news articles present a mixed picture, with some raising valuation concerns while others highlight potential upsides.
*   **Analyst Discrepancy:** While analyst consensus is "Buy," the average target price is slightly below the current price.
*   **Strong Financials:** JNJ exhibits strong profitability and a healthy balance sheet, as indicated by the high profit margins and increasing equity.
*    **Hybrid signal**: The hybrid signal recommends buying the stock.
*   **Negative Long-Term Outlook:** The significantly negative expected return suggests potential underperformance relative to the S&P 500 over the long term.

**Conclusion:**

JNJ presents a mixed investment picture. While it exhibits strong financial fundamentals and has demonstrated recent short-term positive momentum, its underperformance relative to the S&P 500, overbought condition, and negative long-term outlook warrant caution. Investors should carefully consider these factors and conduct further research before making an investment decision.

